ALBIS unveils next-gen healthcare materials at COMPAMED 2025

ALBIS will present a selection of advanced materials from its broad healthcare portfolio

Abbott unveils new diabetes care formula amid rising global diabetes crisis

The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health

Merck to acquire Cidara Therapeutics for $9.2 billion

Diversifying its portfolio to include late-phase antiviral agent

Zydus receives final approval from USFDA for Leuprolide Acetate injection

Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer

LANXESS set to showcase cutting-edge infection control solutions

LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions

Zydus receives FDA final approval for Diroximel fumarate delayed-release capsules, 231 mg

Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis

Merck KGaA Q3 2025 net sales remains flat amid geopolitical uncertainty

Hormone therapy for menopause gets green light from FDA

The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature

Novartis opens radioligand therapy facility in Carlsbad, US

Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio

UK MHRA finds gut microbiome research unreliable across labs

False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample